The study was designed with three co-primary endpoints: OS in a) patients with a PD-L1 CPS ≥ 10; b) patients with ESCC; c) patients in the intention to treat (ITT), entire trial population. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.